SEARCH

SEARCH BY CITATION

References

  • 1
    Gudjonsson JE, Elder JT. Psoriasis. In: Fitzpatrick's Dermatology in General Medicine (Goldsmith LA, Katz SI, Gilchrest BA, Paller A, Leffell DJ, Wolff K, eds), 8th edn. New York: McGraw-Hill Medical, 2012; 197232.
  • 2
    Papp K, Gulliver W, Lynde C et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011; 15:21019.
  • 3
    Williams SC. New biologic drugs get under the skin of psoriasis. Nat Med 2012; 18:638.
  • 4
    Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm 2010; 7:41.
  • 5
    Ghoreschi K, Jesson MI, Li X et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186:423443.
  • 6
    Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178:26239.
  • 7
    O'Sullivan LA, Liongue C, Lewis RS et al. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 2007; 44:2497506.
  • 8
    Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71:4407.
  • 9
    Boy MG, Wang C, Wilkinson BE et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009; 129:2299302.
  • 10
    Papp K, Menter A, Strober B et al. Efficacy and safety of tofacitinib, an oral JAK inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:66877.
  • 11
    Burmester G, Blanco R, Charles-Schoemann C et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month Phase 3 study. Arthritis Rheum 2011; 63(Suppl. 10):S279.
  • 12
    van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month Phase 3 study. Arthritis Rheum 2011; 63(Suppl. 10):S107.
  • 13
    Kremer JM, Li ZG, Hall S et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with traditional DMARDS: a Phase 3 efficacy and safety study in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Ann Rheum Dis 2011; 70:170.
  • 14
    Fleischmann R, Cutolo M, Genovese MC et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64:61729.
  • 15
    Kremer JM, Cohen S, Wilkinson BE et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64:97081.
  • 16
    Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495507.
  • 17
    van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367:50819.
  • 18
    Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367:61624.
  • 19
    Racz E, Prens EP. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med 2009; 11:e38.
  • 20
    Hirahara K, Ghoreschi K, Laurence A et al. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 2010; 21:42534.
  • 21
    Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496509.
  • 22
    Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009; 100(Suppl. 2):213.
  • 23
    Punwani N, Scherle P, Flores R et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67:65864.
  • 24
    van der Velden, Pasch MC, Van Erp PE et al. Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study. J Dermatolog Treat 2010; 21:1322.
  • 25
    Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997; 137:5816.
  • 26
    Zhu X, Wang B, Zhao G et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007; 21:46672.